Multidisciplinary Iberian document Dr. Patricio Aguiar Dr. Miguel F. Gago Dra. María Guedes Marques Dr. Álvaro Hermida Dr. Raúl Jesús Noguera

Fabry disease: Prototype of Lysosomal Storage Disorder with systemic involvementComment on “Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry

Microsoft PowerPoint - Fabry and Females 2022 AKFv11_Wallace Version FinalFabry Disease and Women: The Role of Nephrologists in Diagnosis and Management September 20, 2022

Fabry Disease: Thirty-Five Mutations in the a-Galactosidase A Gene in Patients with Classic and Variant Phenotypes Christine M. Eng,*,t Grace A. Ashley,* Tania S. Burgert,*

Microsoft Word - Tuttolomondo-MSCurrent Pharmaceutical Design, 2013, 19, 000-000 1 1381-6128/13 $58.00+.00 © 2013 Bentham Science Publishers Anderson-Fabry Disease:

GREGORY M. PASTORES,* YEONG-HAU H. LIEN† *Neurogenetics Program, Department of Neurology and Pediatrics, New York University School of Medicine, New York, New York;

HSE Guidelines for the treatment of Fabry DiseasePublished: February 2022 Review: February 2025 Version number: 1 Protocol Code: ERT001 Approved by: Dr Mike O’Connor

ONLINE MUTATION REPORT Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers A Morrone, C Cavicchi, T Bardelli, D Antuzzi,

Introduction lysosomal storage disorder, characterised by the accumulation of globotriasylceramide (GL3) in tissues throughout the body.1 Deficiency of the lysosomal enzyme

Migalastat for treating Fabry diseaseHighly specialised technologies guidance Published: 22 February 2017 www.nice.org.uk/guidance/hst4 © NICE 2022. All rights reserved.